Abstract

The pathology Alzheimer’s disease (AD) is associated with the self-assembly of amyloid-β (Aβ) peptides into β-sheet enriched fibrillar aggregates. A promising treatment strategy is focused on the inhibition of amyloid fibrillization of Aβ peptide. Fullerene C60 is proved to effectively inhibit Aβ fibrillation while the poor water-solubility restricts its use as a biomedicine agent. In this work, we examined the interaction of fullerene C60 and water-soluble fullerenol C60(OH)6/C60(OH)12 (C60 carrying 6/12 hydroxyl groups) with preformed Aβ40/42 protofibrils by multiple molecular dynamics simulations. We found that when binding to the Aβ42 protofibril, C60, C60(OH)6 and C60(OH)12 exhibit distinct binding dynamics, binding sites and peptide interaction. The increased number of hydroxyl groups C60 carries leads to slower binding dynamics and weaker binding strength. Binding free energy analysis demonstrates that the C60/C60(OH)6 molecule primarily binds to the C-terminal residues 31–41, whereas C60(OH)12 favors to bind to N-terminal residues 4–14. The hydrophobic interaction plays a critical role in the interplay between Aβ and all the three nanoparticles, and the π-stacking interaction gets weakened as C60 carries more hydroxyls. In addition, the C60(OH)6 molecule has high affinity to form hydrogen bonds with protein backbones. The binding behaviors of C60/C60(OH)6/C60(OH)12 to the Aβ40 protofibril resemble with those to Aβ42. Our work provides a detailed picture of fullerene/fullerenols binding to Aβ protofibril, and is helpful to understand the underlying inhibitory mechanism.

Highlights

  • Amyloids are involved in a broad range of neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s diseases [1,2,3]

  • The C60(OH)6 molecule has higher affinity to bind to elongation surfaces than C60 and C60(OH)12, which makes C60(OH)6 a more effective inhibitor

  • Sites and interactions of the C60/C60(OH)6/C60(OH)12 nanoparticle binding to Aβ42/40 protofibrillar trimer by performing extensive atomistic molecular dynamics (MD) simulations

Read more

Summary

Introduction

Amyloids are involved in a broad range of neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s diseases [1,2,3]. An increasing number of experimental and computational studies have reported that Aβ aggregation can be modulated by nanoparticles [12,13,14], small molecules [15,16], short peptides [17,18], antibodies [19] and metal ions [20]. Their findings provided new clues for the design of inhibitors targeting Aβ formation. Fullerene derivatives are reported to have remarkable anti-amyloid properties for Alzheimer’s disease and other neurodegenerative diseases [24,25,26,27,28]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.